摘要
目的:研究碳青霉烯联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌呼吸机相关性肺炎的临床疗效。方法:选取北海市人民医院在2014年6月—2016年1月收治的泛耐药鲍氏不动杆菌呼吸机相关性肺炎患者98例,采用碳青霉烯联合头孢哌酮/舒巴坦治疗,观察并记录患者临床治疗疗效、细菌清除率、C反应蛋白、肝肾功能有无变化及不良反应情况。结果:治疗总有效率达到86.73%,治愈率达64.29%;细菌清除率到达64.29%;患者治疗前后红细胞、血小板、总胆红素、尿素氮、肌酐比较无差异(P>0.05),白细胞、中性粒细胞、谷丙转氨霉、CRP、PCT治疗后表达水平明显下降(P<0.05);患者在治疗过程中未出现明显不良反应。结论:碳青霉烯联合头孢哌酮/舒巴坦对治疗泛耐药鲍曼不动杆菌引起的呼吸机相关性肺炎具有较好的临床治疗疗效,并且无明显不良反应。
Objective： To investigate the effecacy of carbapenem combined with cefoperazone/sulbactam for XDRAB ventilator associated pneumonia. Methods： 98 cases with XDRAB VAP in Beihai People＇s Hospital from June 2014 to January 2016 were selected and treated by carbapenem combined with cefoperazone/sulbactam. The effecacy, bacteria clearance rate, C-reactive protein, hepatorenal function and adverse reactions were observed and recorded. Results： The total effective rate, cure rate and bacteria clearance rate reached to 86.73%, 64.29%, and 64.29%, respectively; red blood cell, blood platelet, T-BIL, urea nitrogen, and creatinine were compared before and after treatment and showed no changes （P〉0.05）, hemameba, neutrophil, glutamic-pyruvic transaminase, CRP, and PCT declined obviously after treatment （P〈0.05）; no adverse reactions occurred during treatment. Conelusion： The application of carbapenem combined with cefoperazone/sulbactam for XDRAB ventilator associated pneumonia achieved a satisfactory therapeutic effects, and no adverse reactions occurred during the treatment.
出处
《临床药物治疗杂志》
2017年第5期35-38,共4页
Clinical Medication Journal
